Aegerion Hit With Shareholder Suit Over Juxtapid Labeling
Aegerion Pharmaceuticals Inc. was hit with a proposed class action in Massachusetts federal court Wednesday accusing the biopharmaceutical company of misleading shareholders about off-label marketing of its flagship cholesterol drug Juxtapid....To view the full article, register now.
Already a subscriber? Click here to view full article